Vincent Mancuso

Why is bioconjugate manufacturing receiving so much attention across the pharmaceutical industry?

Bioconjugates represent a significant evolution in how therapies are designed and delivered.

For many years, drug development focused on either small molecules or biologics as separate modalities. Bioconjugates bring together the strengths of both by combining a targeting molecule, such as a monoclonal antibody, with a specialized payload designed to achieve a specific therapeutic outcome.

As these therapies become more prevalent, manufacturers are being challenged to support increasingly complex production parameters while maintaining product quality, safety, and scalability. The manufacturing process requires a high degree of expertise across drug substance production, analytical characterization, formulation and lyophilization development, and sterile fill/finish operations.

As the market continues to grow, organizations are looking for more than manufacturing capacity. They are seeking partners that can simplify development and reduce technical and operational risk.
 

What are the biggest manufacturing challenges companies face when developing bioconjugates?

The greatest challenge is often fragmentation.

Historically, companies have needed multiple specialized partners to support different stages of development. One organization or manufacturing site may manufacture the payload, another may perform bioconjugation, a third may handle formulation development, and a fourth may complete sterile fill/finish activities. That approach can create lengthy timelines, repeated material transfers, additional analytical requirements, and increased supply chain complexity.

Every handoff introduces risk. Knowledge can be lost between organizations, testing requirements can be duplicated, and project timelines become heavily dependent on coordination between multiple external partners.
 

Why is integration becoming such an important differentiator in bioconjugate manufacturing?

Integration creates operational efficiencies that are difficult to achieve when multiple organizations or manufacturing sites are involved.

When drug substance and drug product activities are coordinated within a single development strategy, teams can accelerate decision-making, reduce unnecessary testing, streamline analytical activities, and minimize supply chain risks. Simtra BioPharma Solution’s model is designed around creating these synergies between drug substance and drug product operations within a single manufacturing site, under one-roof.

Just as importantly, integration improves continuity.

When scientific, operational, and analytical teams collaborate from the beginning of a project, they develop a deeper understanding of critical process parameters and product-specific requirements. That knowledge remains connected throughout development rather than being transferred between organizations at multiple stages.

For increasingly complex molecules, maintaining that continuity can have a meaningful impact on both development timelines and overall program execution.
 

How important is manufacturing flexibility in the bioconjugate space?

Flexibility has become essential.

Bioconjugates are not one-size-fits-all therapies. Different molecules often require different conjugation approaches, payloads, analytical strategies, formulations, and manufacturing processes. Customers need the ability to select the conjugation science that best fits their molecule rather than adapting their molecule to fit a manufacturing platform.

That is why platform-agnostic manufacturing capabilities are becoming increasingly attractive.

A flexible manufacturing environment can support a broad range of starting materials, conjugation approaches, and payload types while allowing sponsors to make decisions based on scientific requirements rather than manufacturing constraints. Simtra’s approach is designed around this flexibility, including the ability to support both cytotoxic and non-cytotoxic payloads.

As therapeutic pipelines diversify, maintaining that flexibility will become increasingly important.

What technical capabilities are most critical for successful bioconjugate manufacturing?

Successful bioconjugate manufacturing requires far more than conjugation expertise alone. The most effective programs are built on a combination of advanced chemistry capabilities and the biological and process development knowledge required to translate innovation into scalable manufacturing.

Organizations must understand how manufacturing decisions influence product quality, process robustness, scalability, and long-term commercial performance. That includes expertise in process development, analytical characterization, containment strategies, formulation and sterile manufacturing,

Analytical capabilities are particularly important because bioconjugates require extensive characterization throughout development and manufacturing. Critical quality attributes such as purity, degradation products, drug-to-antibody ratio, potency, identity, and stability all require sophisticated analytical approaches to ensure product quality and consistency.

The strongest manufacturing organizations bring these disciplines together as part of a connected technical strategy rather than treating them as independent activities.

How do you see the bioconjugate manufacturing landscape evolving over the next decade?

The industry will continue moving towards greater integration.

As molecule complexity rises and development timelines accelerate, growing cost pressures will drive increased demand for integrated development models that reduce operational complexity, improve efficiency, and provide access to specialized technical expertise.

At the same time, demand will continue growing for flexible manufacturing platforms, advanced analytical capabilities, high-containment operations, and partners that can seamlessly support both drug substance and sterile drug product manufacturing.

Ultimately, the future of bioconjugate manufacturing will be defined by organizations that can provide an integrated, coordinated solution that seamlessly connects scientific expertise, development, and manufacturing.

The companies that successfully eliminate fragmentation will be best positioned to accelerate development, reduce risk, and bring innovative therapies to patients more efficiently.

Final Thought

The future of bioconjugate manufacturing lies in integrating development and manufacturing into a seamless, end-to-end strategy. Bringing drug substance development and manufacturing, including conjugation and purification, together with drug product development, formulation, lyophilization, and manufacturing at a single site helps reduce complexity, preserve knowledge, minimize handoffs, and accelerate speed to market.